Poloxamer-Based In Situ Nasal Gel of Naratriptan Hydrochloride Deformable Vesicles for Brain Targeting.

Migraine is the chronic neurological disorder identified by recurrent moderate to severe headache. Research was highlighted to formulate target drug delivery to treat migraine via the olfactory lobe through the intranasal route using ethosomal thermoreversible gel. Ethosomes were prepared by thin film hydration method using 3² factorial design. The prepared ethosomes were evaluated for percent drug loading, vesicle size, zeta potential, and polydispersity index, whereas nanoethosomal in situ gels were assessed for their pH, viscosity, mucoadhesive strength, and in vitro drug release. Ex vivo drug permeation was evaluated using nasal mucosa of sheep. The data produced from the experimental design indicated NE6 (soya lecithin 3%:ethanol 50%) as the optimized ethosome formulation, whereas NG3 (carbol 934-0.3%) and NG6 (PVP K30-0.3%) were recorded as the optimized in situ gel formulations. In vitro and ex vivo drug release demonstrated almost 100% release after 24 h for optimized formulations. In conclusion, drug-loaded in situ mucoadhesive gels could release the drug for longer duration of time which can improve the bioavailability providing new dimension to the treatment of migraine. [ABSTRACT FROM AUTHOR]